Ultrasound Neurotechnology: A Quiet Revolution in Mental Health Treatment

by Rebeca Ianov Vitanov University of Cambridge

Introduction: Why Neurotechnology Needs Sound

Depression, ADHD, and related neuropsychiatric conditions represent one of the largest and most persistent burdens on global health systems. In the UK alone, millions live with mood and attention disorders that impair quality of life, productivity, and long-term wellbeing. Despite decades of progress, current treatments remain blunt instruments: psychopharmacology is often diffuse and side-effect-laden; talk therapy is resource-intensive and slow to scale; and more invasive interventions are reserved for the most severe cases.

The result is a widening gap between what neuroscience understands about the brain, as a dynamic, networked system, and how mental health care is delivered in practice.

Into this gap enters ultrasound-based neuromodulation: a rapidly emerging neurotechnology that uses sound waves, rather than electricity or magnetism, to modulate brain activity with remarkable spatial precision. Once confined to imaging, ultrasound is now being explored as a therapeutic modality capable of targeting deep brain circuits non-invasively and reversibly.

This is no longer science fiction. Clinical studies are already under way, and regulatory conversations have begun. The question is no longer whether ultrasound can modulate brain activity, but whether health systems are ready to make practical use of what it enables.

What Is Ultrasound Technology in Neurotech?

Ultrasound refers to high-frequency sound waves beyond the range of human hearing. While traditionally used for diagnostic imaging, it is increasingly being repurposed in neurotechnology to modulate neural activity non-invasively. At low intensities, ultrasound can reversibly influence neuronal excitability and circuit dynamics without implants or incisions, making it especially relevant for psychiatry, cognition, and next-generation brain interfaces.

At a mechanistic level, focused ultrasound is thought to act through a combination of mechanical forces, microscale thermal effects, and, under some conditions, cavitation, all of which can alter neuronal membranes and ion channel dynamics. Crucially, these effects can be delivered with millimeter-scale spatial precision, including in deep and subcortical brain regions. This places ultrasound in a rare “sweet spot” in neurotechnology: it can access deep brain circuits like invasive deep brain stimulation (DBS), while remaining non-invasive like transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS), without their spatial or depth limitations.

Focused ultrasound: aiming sound like a lens

Focused ultrasound (FUS) captures the core idea: multiple ultrasound waves are steered so their energy converges on a small region of the brain, a bit like using a magnifying glass to focus sunlight. The beam can be shaped and steered to reach both cortical areas and deep structures like the thalamus or amygdala, all from outside the skull.

Within FUS, there are two broad regimes:

• High‑intensity focused ultrasound (HIFU), used clinically to create small lesions; for example, treating essential tremor by ablating a precise target.

• Low‑intensity focused ultrasound (LIFU), used to modulate activity without destroying tissue, briefly nudging neurons and networks rather than burning or cutting.

Focused ultrasound neuromodulation. The potential biophysical effects of ultrasonic neuromodulation. From Liu et al., 2022.

Low‑intensity focused ultrasound (LIFU/tFUS/TUS)

In the neuromodulation literature, several acronyms appear:

• LIFU: low‑intensity focused ultrasound

• tFUS: transcranial focused ultrasound

• TUS: transcranial ultrasound stimulation

All of them point to the same basic concept: send low‑intensity, focused ultrasound through the skull to modulate activity in a specific brain region, without heating it enough to cause damage. Parameters like frequency, intensity, and timing can be tuned to shape the effect.

Depiction of a typical set-up for human low-intensity focused ultrasound (LIFU) experiments. From Legon & Strohman, 2024.

LIFU is interesting for psychiatry for several reasons:

• It is non‑invasive and reversible, so stimulation can be switched on and off and adjusted across sessions.

• It can reach deep targets that are hard to access with tools like TMS, opening opportunities to directly probe circuits underlying mood, anxiety, or memory.

• It appears able to both enhance and suppress activity, depending on the protocol, creating a rich design space for therapeutic strategies.

Pulsed paradigms: transcranial pulsed ultrasound (TPU)

Most real‑world neuromodulation protocols do not deliver ultrasound as a continuous “on” signal. Instead, they use pulses – i.e. bursts of ultrasound separated in time. This is often referred to as transcranial pulsed ultrasound (TPU), but it’s best understood as a way of driving LIFU/tFUS rather than as a separate modality.

In pulsed paradigms, several timing variables matter:

• Pulse repetition frequency (PRF): how many bursts occur per second

• Duty cycle: what fraction of each second the ultrasound is actually on

• Burst duration and pattern: how long each burst lasts, and how bursts are grouped over time

Changing these parameters can shift the outcome of stimulation: for example, biasing towards excitation vs inhibition, or targeting brief state changes vs longer‑lasting plasticity. From a design perspective, this is where much of the “protocol intelligence” lives: the same hardware can behave very differently depending on how it is pulsed.

Clinical Potential: Depression, ADHD, and Beyond

Depression Mood disorders are increasingly understood as disorders of distributed brain networks, not just “chemical imbalance.” Circuits linking prefrontal cortex, limbic regions, and subcortical hubs are central to affect regulation. Early pre‑clinical and human studies suggest that low‑intensity focused ultrasound can modulate these circuits with measurable behavioural and neurophysiological effects, with a safety and side‑effect profile that looks different from medication or electroconvulsive therapy (ECT.) While still early‑stage, this work is beginning to test whether brief, reversible modulation can shift depressive symptoms in clinically meaningful ways. Publicly funded programmes in the UK and internationally are now investing substantial resources in ultrasound-based interventions for mood disorders, signalling growing institutional confidence in the approach.

ADHD ADHD involves disruptions in attentional control, executive function, and reward processing across fronto‑striatal networks. In principle, ultrasound’s ability to target these circuits with millimetre‑scale precision makes it a compelling candidate for attentional modulation, especially when medication is poorly tolerated or only partially effective. Dedicated ADHD trials are still sparse, but converging evidence from related psychiatric and cognitive domains makes this an area to watch.

Beyond Mental Health The pipeline goes well beyond depression and ADHD. Ultrasound neuromodulation is being explored for chronic pain, addiction, Alzheimer’s and Parkinson’s disease, disorders of consciousness, and cognitive rehabilitation. Most of this work is early‑stage, but the breadth of indications points to a simple idea: sound may become a new kind of therapeutic interface with the brain.

From Symptom Management to System‑Level Modulation

What makes ultrasound exciting is not just how it works, but what it represents. Mental health disorders are increasingly seen as system‑level dysregulations in networks, yet most treatments still act indirectly: globally shifting neurotransmitters or relying on slow behavioural change. Ultrasound introduces a third option: precise, reversible, circuit‑level modulation. Instead of only dampening symptoms or waiting for long‑term plasticity, clinicians could one day tune dysfunctional networks in near real time, guided by imaging, biomarkers, or behaviour. That nudges psychiatry from static diagnosis toward dynamic regulation.

Why Ultrasound Stands Out

Ultrasound holds up surprisingly well in relation to other neuromodulation techniques:

• Versus TMS/tDCS: reaches deeper targets with much finer spatial precision.

• Versus DBS: offers access to similar circuits without surgery, implants, or infection risk.

• Versus pharmacology: effects can be local, parameter‑tuned, and rapidly reversible.

In that sense, ultrasound acts like a bridge: combining the safety profile of non‑invasive stimulation with a level of precision that used to require neurosurgery.

Barriers and the UK Opportunity

The UK excels at neurotech discovery but lags in delivery. Brain disorders already cost £96 billion yearly (4.3% of GDP); optimising existing tools could save £30+ billion.​

Key bottlenecks include:

• Commissioning delays. MHRA approval is fast, but NICE cost-effectiveness reviews often demand extra UK data, leaving proven devices in limbo for years.​

• Capacity shortages. The UK has around half the EU average of neurologists and specialist nurses, and long waiting times combined with poor referral pathways mean that even commissioned technologies remain underused.

• R&D hurdles. No early-feasibility pathways, short funding cycles, and limited trial infrastructure make first-in-human studies harder here than in the US.

For ultrasound and other neurotechnologies, this creates a familiar pattern: innovation here, implementation elsewhere.

How the UK Can Move Faster

The Centre for British Progress report argues that the UK can still lead, but only if it tackles commissioning and early‑stage research head‑on. For ultrasound neurotechnology, five moves would make a real difference:

1. Conditional commissioning pilots. Post-MHRA: Accelerated mandates for cost-saving therapies; managed access for high-value ones targeting £15,000/QALY, with risk-sharing rebates.​

2. Embed neurotech fellows. Fund 10 seven-year roles in NHS teams for care, trials, and referrals.​

3. Neurotech Clinical Leads. Pilot in 3 centres to map patients, educate referrers, and track uptake.​

4. MHRA early-feasibility route. Dedicated small-N pathway plus reference files to cut duplication (like FDA's model).​

5. Trial support hubs. NIHR reimburses NHS costs for approved studies; build 3+ NHS-university hubs with stewards and grants.​

Conclusions

Ultrasound neuromodulation is quiet, both literally and metaphorically, but its implications are transformative. It challenges us to reimagine mental health care as tunable, precise, and adaptive; regulators to modernise pathways built for drugs, not dynamic circuits; and health systems to choose whether they lead or follow the neurotherapeutics revolution.

Yet precision brings responsibility. Ultrasound raises important ethical questions around unintended modulation, long-term safety, consent, and patient agency – questions that call for thoughtful, evolving governance rather than after-the-fact safeguards. While current evidence for low-intensity approaches is encouraging, regulatory and ethical oversight will need to advance in step with the technology.

Ultrasound does not simply ask whether a device works; it asks whether our institutions are prepared for a new era of neuroscience. The sound is already here. The challenge now is whether we are ready to respond.

References

Badran, B.W., Peng, X. Transcranial focused ultrasound (tFUS): a promising noninvasive deep brain stimulation approach for pain. Neuropsychopharmacol. 49, 351–352 (2024). https://doi.org/10.1038/s41386-023-01699-w .

Brannigan, J., & Powell, R. (2025, October 29). Breaking down barriers to help the UK embrace neurotechnology. Centre for British Progress. https://britishprogress.org/briefings/breaking-down-barriers-to-help-the-uk-embrace-neur#Authors .

Legon, W., Strohman, A. Low-intensity focused ultrasound for human neuromodulation. Nat Rev Methods Primers 4, 91 (2024). https://doi.org/10.1038/s43586-024-00368-6 .

Liu, X., Qiu, F., Hou, L., & Wang, X. (2022). Review of Noninvasive or Minimally Invasive Deep Brain Stimulation. Frontiers in behavioral neuroscience, 15, 820017. https://doi.org/10.3389/fnbeh.2021.820017

Tan, G., Chen, H., & Leuthardt, E. C. (2025). Ultrasound applications in the treatment of major depressive disorder (MDD): A systematic review of techniques and therapeutic potentials in clinical trials and animal model studies. medRxiv: the preprint server for health sciences, 2025.01.23.25320960. https://doi.org/10.1101/2025.01.23.25320960 .